Case studies of AI enabled RWE projects informing regulatory decisions Case Studies of AI Enabled RWE Projects Informing Regulatory Decisions Introduction to AI in Real-World Evidence (RWE) Real-world evidence (RWE) has emerged as a crucial component in informing regulatory decisions. The incorporation of advanced analytics, artificial intelligence (AI), and machine learning (ML) in analyzing real-world data (RWD) has enhanced the ability to generate insights that align with regulatory expectations, especially from the U.S. Food and Drug Administration (FDA). As pharmaceutical and medtech companies strive to demonstrate the value of their products, leveraging AI and machine learning techniques, such as ML…

Causal Inference Techniques and ML Hybrids for Regulatory Grade RWE Introduction to Advanced Analytics in RWE for FDA Submissions As the landscape of healthcare evolves, regulatory agencies like the US Food and Drug Administration (FDA) are increasingly incorporating real-world evidence (RWE) in their decision-making processes. Advanced analytics, including artificial intelligence (AI) and machine learning (ML) techniques, are revolutionizing the way RWE is generated, analyzed, and utilized. This tutorial outlines the step-by-step approach to implementing causal inference techniques and ML hybrids that meet the stringent requirements for regulatory submissions. The advent of electronic health records (EHRs), claims data, and other real-world…

Unlocking Unstructured EHR Notes for RWE: A Step-by-Step Guide to NLP and Advanced Analytics for FDA Submissions Natural Language Processing (NLP) and advanced analytics, including machine learning (ML), provide unprecedented opportunities for pharmaceutical and medical technology companies to harness the wealth of information contained in electronic health records (EHR). As regulatory scrutiny intensifies around real-world evidence (RWE) submissions to the FDA, understanding how to effectively implement NLP techniques becomes paramount. This article provides a step-by-step tutorial on using NLP to unlock unstructured EHR notes and how this aligns with FDA requirements for RWE submissions. Understanding the FDA’s Perspective on Real-World…

Machine Learning Methods for Phenotyping and Cohort Selection in Real-World Evidence Studies The integration of advanced analytics, particularly through machine learning (ML) techniques, is revolutionizing the approach to real-world evidence (RWE) studies. Regulatory bodies, including the FDA, are increasingly recognizing the value that robust data analytics, exemplified by ML methods, can bring to clinical research and health outcomes evaluations. This article serves as a comprehensive tutorial for professionals in regulatory affairs, biostatistics, health economics and outcomes research (HEOR), RWE, and data standards, focusing on the application of machine learning in phenotyping and cohort selection for FDA submissions. Understanding Real-World Evidence…

Using Advanced Analytics and Artificial Intelligence in Real World Evidence for FDA Submissions The integration of advanced analytics, artificial intelligence (AI), and machine learning (ML) into real-world evidence (RWE) is transforming how pharmaceutical and medical technology companies approach regulatory submissions to the U.S. Food and Drug Administration (FDA). In this tutorial, we will discuss the regulatory landscape, methodologies, and best practices for leveraging these technologies to support FDA submissions. Understanding Real-World Evidence and its Regulatory Context Real-world evidence is derived from data gathered outside of traditional clinical trials. This data encompasses various sources, such as electronic health records (EHR), claims…

Combining Bayesian Methods and Machine Learning for Small Sample RWE Settings As the landscape of drug development evolves, the integration of advanced analytics, artificial intelligence (AI), and machine learning (ML) into real-world evidence (RWE) generation has gained significant traction. This article aims to provide a comprehensive step-by-step tutorial on how to effectively utilize Bayesian methods alongside machine learning in small sample RWE settings, particularly within the context of U.S. FDA submissions. Understanding Real-World Evidence (RWE) and Its Importance Real-world evidence refers to the clinical evidence derived from the analysis of real-world data (RWD). This data is collected outside of conventional…

Explainability and Transparency Standards for ML Driven RWE Results The adoption of machine learning (ML) in generating real-world evidence (RWE) has been transformative for the pharmaceutical and biotech industries. However, as the FDA intensifies its focus on the reliability and credibility of data derived from these technologies, understanding the associated standards for explainability and transparency becomes paramount. This article delineates a step-by-step approach, highlighting key considerations and guidelines relevant for organizations preparing FDA submissions involving advanced analytics, AI, and machine learning technologies. Understanding the FDA’s Perspective on ML in RWE The FDA has ramped up efforts to regulate the use…

Managing Bias Amplification Risks in Advanced Analytics with AI and Machine Learning for FDA Submissions In recent years, the integration of advanced analytics, artificial intelligence (AI), and machine learning (ML) into real-world data (RWD) analysis has transformed how pharmaceutical and medical technology companies conduct study designs, healthcare outcomes research, and regulatory submissions. However, this shift carries significant challenges, including the risk of bias amplification. This tutorial serves as a comprehensive guide for regulatory, biostatistics, Health Economics and Outcomes Research (HEOR), and RWD data standards professionals seeking to understand and mitigate these risks when applying AI technologies in FDA submissions. 1….

Governance for Responsible AI Use in RWE Pipelines and Submissions The integration of advanced analytics, artificial intelligence (AI), and machine learning (ML) into real-world evidence (RWE) pipelines has become increasingly significant in regulatory submissions to the US FDA. As regulatory expectations evolve, professionals in the pharmaceutical and medtech sectors must be equipped with a solid understanding of AI governance to ensure compliance with various regulatory standards. In this step-by-step tutorial, we will explore best practices, considerations, and frameworks for the responsible use of AI and analytics within RWE submissions, providing a comprehensive overview for regulatory, biostatistics, Health Economics and Outcomes…

Validation Expectations When Using ML Models in RWE Analyses Real-World Evidence (RWE) has become increasingly significant in the regulatory landscape, particularly for the validation of advanced analytics involving machine learning (ML) in FDA submissions. As regulatory expectations evolve, it is critical for professionals in the fields of regulatory affairs, biostatistics, and health economics and outcomes research (HEOR) to ensure compliance with rigorous standards. This article provides a comprehensive step-by-step regulatory tutorial on validation expectations when employing ML models in RWE analyses, with a primary emphasis on submissions to the U.S. FDA. Overview of Real-World Evidence and Regulatory Context RWE is…